MWNA
RAPT

Marshall Wace North America’s RAPT Therapeutics RAPT Stock Holding History

Marshall Wace North America’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$3.28M Sell
13,202
-5,685
-30% -$1.5M 0.01% 610
2021
Q2 		$4.8M Buy
+18,887
New +$3.53M 0.02% 560

Other funds holding RAPT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace North America's RAPT Position: Q3 2021 in Review

Marshall Wace North America reduced its RAPT Therapeutics (RAPT) stake by 30% in Q3 2021, selling an estimated $1.5M and leaving 13,202 shares worth $3.28M. The position accounts for 0.01% of the portfolio, ranked #610.

Marshall Wace North America first reported a position in RAPT in Q2 2021 and has held it in 2 quarters since. The position peaked at $4.8M in Q2 2021. 106 funds tracked by Wall St. Rank hold RAPT as of Q3 2021.

  • Marshall Wace North America held 13,202 shares of RAPT Therapeutics worth $3.28M as of Q3 2021.
  • Marshall Wace North America sold 5,685 RAPT Therapeutics shares in Q3 2021, an estimated $1.5M.
  • RAPT Therapeutics made up 0.01% of Marshall Wace North America's portfolio in Q3 2021, its #610 holding.
  • Marshall Wace North America first reported a position in RAPT Therapeutics in Q2 2021 and has held it in 2 quarters since.
  • Marshall Wace North America's RAPT Therapeutics position peaked at $4.8M in Q2 2021.
  • 106 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.